Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. However, there are no published data on the efficacy of antiviral therapy in Korea. We assessed the safety and efficacy of combination therapy with peginterferon α-2a plus ribavirin for CHC in hemophilia. Methods: Patients (n=115) were enrolled between March 2007 and December 2008. Seventy-seven patients were genotype 1 or 6, and 38 patients were genotype 2 or 3. We evaluated rapid virologic responses (RVRs), early virologic response (EVRs), end-of-treatment response (ETRs), sustained virologic response (SVRs), and relapses. Safety evaluations included adverse events and laboratory tests. Results: Eleven patients were excluded from the study because they had been treated previously. Among the remaining 104 treatment-naïve patients, RVR was achieved in 64 (60.6%), ETR was achieved in 95 (91.3%), and SVR was achieved in 89 (85.6%). Relapse occurred in eight patients (8.9%). Common adverse events were hair loss (56.7%) and headache (51.0%). Common hematologic adverse events were neutropenia (22.1%), anemia (27.9%), and thrombocytopenia (3.8%). However, there were no serious adverse events such as bleeding. RVR was the only predictor of SVR in multivariate analysis. Conclusions: Peginterferon α-2a plus ribavirin combination treatment produced a favorable response rate in CHC patients with hemophilia without serious adverse events. (Clin Mol Hepatol 2015;21:125-130)
Abstract
Background/Aims: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. However, there are no published data on the efficacy of antiviral therapy in Korea. We assessed the safety and efficacy of combination therapy with peginterferon α-2a plus ribavirin for CHC in hemophilia. Methods: Patients (n=115) were enrolled between March 2007 and December 2008. Seventy-seven patients were genotype 1 or 6, and 38 patients were genotype 2 or 3. We evaluated rapid virologic responses (RVRs), early virologic response (EVRs), end-of-treatment response (ETRs), sustained virologic response (SVRs), and relapses. Safety evaluations included adverse events and laboratory tests. Results: Eleven patients were excluded from the study because they had been treated previously. Among the remaining 104 treatment-naïve patients, RVR was achieved in 64 (60.6%), ETR was achieved in 95 (91.3%), and SVR was achieved in 89 (85.6%). Relapse occurred in eight patients (8.9%). Common adverse events were hair loss (56.7%) and headache (51.0%). Common hematologic adverse events were neutropenia (22.1%), anemia (27.9%), and thrombocytopenia (3.8%). However, there were no serious adverse events such as bleeding. RVR was the only predictor of SVR in multivariate analysis. Conclusions: Peginterferon α-2a plus ribavirin combination treatment produced a favorable response rate in CHC patients with hemophilia without serious adverse events. (Clin Mol Hepatol 2015;21:125-130)
참고문헌 (19)
- Patel H, "When to treat and the benefits of treating hepatitis C in patients with haemophilia", Haemophilia, 15, pp.20~32 (2009)
- Lee C, "The natural history and antiviral treatment of hepatitis C in haemophilia", Haemophilia, 8, pp.322~329 (2002)
- Posthouwer D, "Treatment of chronic hepatitis C in patients with haemophilia : a review of the literature", Haemophilia, 12, pp.473~478 (2006)
- Maor Y, "Treatment of hepatitis C in patients with haemophilia-the Israeli National Hemophilia Center experience", Haemophilia, 14, pp.336~342 (2008)
- Sinn DH, "Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients", J Gastroenterol Hepatol, 26, pp.1374~1379 (2011)
- Pereira GH, "Treatment of chronic hepatitis C virus infection among Brazilian haemophiliacs", Braz J Infect Dis, 12, pp.20~23 (2008)
- 2009 Annual Report: Korean Hemophilia Foundation 2009, "KHP", 40~
- 2013 Annual Report: Korean Hemophilia Foundation 2013, "KHP", ~
- Liver KTKAftsot, "Guidelines for treatment for Chronic hepatitis C. In", ~ (2013)
- Medrano J, "Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIVuninfected patients", Clin Infect Dis, 49, pp.1397~1401 (2009)
- EASL, "EASL Clinical Practice Guidelines : management of hepatitis C virus infection", J Hepatol, 55, pp.245~264 (2011)
- Franchini M, "Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin : a meta-analysis", J Antimicrob Chemother, 61, pp.1191~1200 (2008)
- Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C : a randomised trial", Lancet, 358, pp.958~965 (2001)
- Alavian SM, "Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection : a single-centre study of 367 cases", Liver Int, 30, pp.1173~1180 (2010)
- Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
- Maor Y, "Hepatitis C at the israeli national hemophilia center", Haemophilia, 12, pp.68~74 (2006)
- Pearlman BL, "Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection : a cure and so much more", Clin Infect Dis, 52, pp.889~900 (2011)
- Ge D, "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance", Nature, 461, pp.399~401 (2009)
- Lyoo K, "Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin", J Clin Virol, 52, pp.363~366 (2011)